132
Participants
Start Date
November 30, 2000
Study Completion Date
August 31, 2006
Ribavirin
Interferon alfa-2a
Peginterferon alfa-2a
Beth Israel Med. Ctr., ACTU, New York
NY Univ. HIV/AIDS CRS, New York
Mt. Sinai Med. Ctr. A0404 CRS, New York
AIDS Care CRS, Rochester
Univ. of Rochester ACTG CRS, Rochester
Philadelphia Veterans Admin. Med. Ctr. A6205 CRS, Philadelphia
The Ponce de Leon Ctr. CRS, Atlanta
Indiana Univ. School of Medicine, Wishard Memorial, Indianapolis
Methodist Hosp. of Indiana, Indianapolis
Univ. of Iowa Healthcare, Div. of Infectious Diseases, Iowa City
University of Minnesota, ACTU, Minneapolis
Univ. of Texas Southwestern Med. Ctr., Amelia Court Continuity Clinic, Dallas
University of Colorado Hospital CRS, Aurora
Ucsd, Avrc Crs, San Diego
Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu
Univ. of Miami AIDS CRS, Miami
Univ. of Cincinnati CRS, Cincinnati
Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis
Ucsf Aids Crs, San Francisco
Massachusetts General Hospital ACTG CRS, Boston
Bmc Actg Crs, Boston
Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston
Brigham and Women's Hosp. ACTG CRS, Boston
HIV Prevention & Treatment CRS, New York
National Institute of Allergy and Infectious Diseases (NIAID)
NIH